Mechanism of action
In preclinical models the reported activity of BPC-157 is described primarily through the nitric oxide system: the peptide modulates NO synthesis (eNOS) and, in rodent experiments, counteracts both NO blockade (L-NAME) and NO excess (L-arginine). Cell-based work reports activation of VEGFR2 with downstream Akt/eNOS signalling, which is linked to the angiogenesis and granulation-tissue formation observed in these models. Further described effects include increased cell migration via the FAK-paxillin pathway, altered expression of Egr-1 and its co-repressor NAB2 in relation to collagen and growth-factor genes, upregulation of the growth hormone receptor in tendon fibroblasts, dampening of pro-inflammatory NF-κB-dependent signalling, and stabilisation of the intestinal barrier. All of these statements come from animal and cell experiments; no mechanism has been confirmed in humans.
State of evidence
The evidence base for BPC-157 is almost entirely preclinical. Numerous rodent studies exist, among them Achilles tendon transection, muscle injury, colitis, NSAID-induced mucosal lesions and fistula models, complemented by in vitro work on fibroblasts and endothelial cells. A large share of these publications originates from the same research group around P. Sikiric in Zagreb and appeared in a narrow set of journals; independent replications and systematic reviews with formal quality appraisal are largely absent. No controlled, peer-reviewed human study with published results is available. Trial registries list a phase 1 study of PCO-02 from 2015 whose status has remained unknown since registration and for which no results are posted, plus a phase 2 trial in acute hamstring injury that started in 2026 and is currently recruiting, likewise without results. There is no medicinal-product approval in any region. For pharmacokinetics, one published animal study exists (He et al., 2022): in rats and beagle dogs the elimination half-life after intravenous administration was below 30 minutes, with absolute intramuscular bioavailability of roughly 14 to 19 percent (rat) and 45 to 51 percent (dog). The multi-hour half-life figures circulating in secondary sources are not supported by these data; robust human data on kinetics, bioavailability and safety are lacking.
Storage and handling
General handling for lyophilized peptides applies: store cool, dry and protected from light, ideally in the original packaging. After reconstitution the solution is typically kept refrigerated at 2 to 8 degrees Celsius and used only for a limited period of a few days to weeks, depending on preparation, solvent and laboratory protocol. Repeated freeze-thaw cycles and prolonged exposure to light or heat are regarded as critical. No robust, substance-specific published stability data exist for BPC-157 in solution.
Questions about the research
- What is BPC-157 investigated for in research?
- Published work deals predominantly with tissue repair in animal models, for example healing of tendon, muscle, skin and bone, and with the integrity of the gastrointestinal mucosa after injury. In vitro studies on fibroblasts and endothelial cells add observations on cell migration and new vessel formation. These research questions describe the context of investigation and say nothing about efficacy in humans.
- What is the state of the evidence on BPC-157?
- The evidence is preclinical: rodent models and cell experiments, largely from a single research group, with little independent replication. No controlled human trials with published results exist; registries list one phase 1 study of unknown status and one recruiting phase 2 trial, neither with results. Statements about efficacy, tolerability or safety in humans are therefore not supported.
Sources
- He et al., Front Pharmacol 2022 (PK in rat and dog)DOI: 10.3389/fphar.2022.1026182PMID: 36588717
- Seiwerth et al., Curr Pharm Des 2018DOI: 10.2174/1381612824666180712110447PMID: 29998800
- Krivic et al., Inflamm Res 2008DOI: 10.1007/s00011-007-7056-8PMID: 18594781
- Hsieh et al., J Mol Med 2017DOI: 10.1007/s00109-016-1488-yPMID: 27847966
- Chang et al., J Appl Physiol 2011DOI: 10.1152/japplphysiol.00945.2010PMID: 21030672
- Chang et al., Molecules 2014DOI: 10.3390/molecules191119066PMID: 25415472
- Park et al., Curr Pharm Des 2020DOI: 10.2174/1381612826666200523180301PMID: 32445447
- ClinicalTrials.gov NCT02637284, PCO-02 phase 1 safety and pharmacokinetics, 2015 (status unknown)
- ClinicalTrials.gov NCT07437547, phase 2 trial in acute hamstring strain, 2026 (recruiting)